Ken Drazan, MD, Head, Johnson & Johnson Innovation Center in California

Ken Drazan leads the Johnson & Johnson Innovation Center in carrying out the organization’s mission to access early external innovation. Ken’s background includes more than 13 years in the healthcare industry and 12 years in the hospital and academic worlds.

Ken works with the California IC Team and partners with the other JJICs and the R&D, business development, and business leaders across Johnson & Johnson to identify, shape and on-board the most promising science and technology opportunities at universities, academic centers, tech- and biotech companies, with the goal of catalyzing early stage innovation and bringing transformative medicines, devices, and consumer products to Johnson & Johnson.

A liver transplant surgeon by training, Ken spent several years at Stanford University before moving into entrepreneurial leadership roles in the biopharmaceutical industry and subsequently in the venture capital world. Ken’s deep background in science, his business experience, and his strong ties to the Bay Area life science community provide a unique combination of skills and expertise to his leadership of our California IC.

Previously, Ken co-founded Bertram Capital Management in 2006. He served as General Partner of this family of growth equity funds focused on middle market equity investments in business services, consumer products, light manufacturing, and healthcare services. He was also Co-Founder and Chairman of EnGen Bio, a virtual company focused on novel therapeutics in infectious disease and oncology.
 
Ken has held a variety of entrepreneurial leadership positions, including Founder, Chief Executive Officer, and Director of Arginox, a venture-backed company developing nitric oxide targeted medicines for critical care. He also held executive positions at Genesoft Pharmaceuticals, Inc., a company that developed anti-infective therapeutics in collaboration with the Department of Defense and for consumer markets.

Ken earned his B.A. in Economics from Yale College and received his M.D. Cum Laude from State University of New York. He completed his residency and Postdoctoral Fellow at UCLA Medical Center, with a focus on surgery and microbiology.   

Kathy Giacomini, PhD, Chair, UCSF Department of Bioengineering and Therapeutic Sciences

Kathleen M. Giacomini, Ph.D., Professor and Chair of the Department of Bioengineering and Therapeutic Sciences, received her Ph.D. in Pharmaceutics from the State University of New York at Buffalo and completed a post-doctoral fellowship at Stanford University. Dr. Giacomini is considered a leader in the field of pharmacogenomics of membrane transporters. She led the discovery of coding region variants of about 50 membrane transporters that play a role in drug response in ethnically diverse populations. Dr. Giacomini has co-authored over 200 manuscripts in peer-reviewed journals and has received many awards for her research including the Dawson Award of the American Association of Colleges of Pharmacy, the Rawls Palmer Award of the American Society for Clinical Pharmacology and Therapeutics, the Therapeutic Frontiers Lecture Award from the American College of Clinical Pharmacy and the Scheele Award from the Swedish Academy of Pharmaceutical Scientists, the DeWitt Stetten Lecturer honor from the National Institute of General Medical Sciences 50th Anniversary and will receive the Distinguished Investigator Award for 2014 from the American College of Clinical Pharmacology. She was inducted into the Institute of Medicine of the National Academies in 2007.

Regis Kelly, PhD, OBE, Director, QB3

Prior to joining QB3 in 2004, Regis Kelly served as executive vice-chancellor at UCSF; he oversaw the UCSF research enterprise and was also responsible for construction of the new Mission Bay campus. Kelly was appointed an Officer of the Order of the British Empire (OBE) in the 2014 New Year Honours for services to science, innovation, and global health. He joined the UCSF Department of Biochemistry in 1971 and has served as director of the Cell Biology Graduate Program, director of the Hormone Research Institute, and chair of the Department of Biochemistry and Biophysics. In 2015, he was awarded the inaugural Byers Family Distinguished Professorship at UCSF. He was chairman of the Bay Area Scientific Innovation Consortium and has served on the boards of the Malaysian Biotechnology Industry Advisory Board, the Scleroderma Research Foundation, and Bridge Pharmaceuticals. He is an advisor to the Thailand Bionanotechnology Institute, Ho Chi Minh City Biotechnology Department Corp., University of Oxford Systems Biology Program, and the San Francisco Mayor’s Biotechnology Advisory Group. Kelly earned an undergraduate degree in physics from the University of Edinburgh and a PhD in biophysics from the California Institute of Technology.

Hanmin Lee, MD, Surgeon in Chief, UCSF Benioff Children's Hospital San Francisco

Dr. Hanmin Lee is director of the UCSF Fetal Treatment Center and surgeon in chief of UCSF Benioff Children's Hospital. He specializes in minimally invasive, fetal and neonatal surgery; bile disorders in infants and children; and the treatment of life-threatening congenital anomalies.

Lee is a professor of clinical surgery, pediatrics, obstetrics, gynecology and reproductive sciences at UCSF, and co-investigator on a number of surgical clinical trials. His interests in research include tissue engineering, blood vessel development and liver regeneration. Lee earned a medical degree at New York University Medical School where he completed general surgery training. He also completed training in pediatric surgery at Emory University and postdoctoral research fellowship at Boston Children's Hospital and Harvard University.

Frank Litvack, MD, FACC, serial entrepreneur

Dr. Litvack is a native of Canada. He completed medical school and an internal medicine residency at McGill University in Montreal and a Cardiovascular Fellowship at Cedars-Sinai Medical Center in Los Angeles, where he subsequently became Co-Director of the Cardiovascular Intervention Center and Professor of Medicine at UCLA. There he led a prominent clinical and research program known for its excellence in innovation, care and leadership in Translational Medicine. Dr. Litvack was Board certified in Internal Medicine, Cardiovascular Diseases and Interventional Cardiology. He has published more than one hundred research articles and chapters and is the recipient of several awards including an American Heart Association Young Investigator Award, the Leon Goldman Medical Excellence Award for contributions to the field of biomedical optics and the United States Space Technology and Space Foundation Hall of Fame for pioneering work with excimer lasers. Dr. Litvack left full time practice and academics in 2000 to concentrate on entrepreneurial activities.

Dr. Litvack has founded and/or operated several healthcare ventures both as chairman and/or CEO, including Advanced Interventional Systems Inc. (merged with Spectranetics Inc.), Progressive Angioplasty Systems Inc., Savacor Inc., Conor Medsystems Inc. and Entourage Medical Technologies Inc. He is presently Executive Chairman of several ventures including Capricor Therapeutics Inc., and Credence MedSystems Inc. He has overseen both the sale and/or public offerings of several of these ventures. Dr. Litvack is a Co-Founder and General Partner in Pura Vida Investments LLC, a health care focused Hedge Fund. In addition he sits on the Boards of several early stage health care companies.  

Allan W. May, Co-Founder, Life Science Angels

Allan is a founder of Life Science Angels, the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals from the medical device or biotech fields. LSA has invested over $40M in 45 startups and achieved 7 positive exits to date.

In 2007, Allan joined renowned inventor, entrepreneur and cardiac surgeon, Dr. Thomas Fogarty, in co-founding Emergent Medical Partners, a venture fund focused on early stage medical device company creation and investing. EMP has invested $55M in 28 startups with 8 positive exits to date.

Allan is a member of the board of both the Kauffman Foundation’s Angel Capital Association and Angel Resource Institute. Until mid-2012, Allan was Chair of ARI, a nonprofit devoted to the promotion and study of angel investing. He was instrumental in the creation of the Halo Report, the first detailed data tracking early stage investment by angel groups.

J. Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati

J. Casey McGlynn, partner at Wilson Sonsini Goodrich & Rosati, joined WSGR in 1978 and formed the Life Sciences Group at the firm in 1990. It is a nationally recognized leader in the representation of startup and emerging growth companies in the life sciences field. Mr. McGlynn has one of the largest practices in the country focused on Medical Devices. Mr. McGlynn has formed, sold and taken public many of the most important medical device companies started during the last 25 years.

Mr. McGlynn has extensive hands on experience in helping entrepreneurs form, build, fund and sell their companies. He has helped to form and participated with the boards of companies in all of the major Medical Device fields, including biologics, cancer, cardiovascular, cardiac surgery, congestive heart failure, cosmetic medicine, diagnostics, electrophysiology, ENT, gastroenterology, general surgery, hearing, imaging, monitoring, neurosurgery, obesity, ophthalmology, orthopedics, peripheral vascular disease, renal therapy, sports medicine, urology, and women’s health.

Over the last 30 years he has built close working relationships with an unparalleled list of entrepreneurs, doctors, investors, engineers, and managers in this industry. Through his portfolio of companies he has met with and negotiated with the leaders of all of the major Medtech acquirers.

Mr. McGlynn was a founding member of BIO and served on the Emerging Company Board of BIO for over a decade. Mr. McGlynn currently serves on the Medical Device Manufacturers Association, a Washington trade organization focused on issues of importance to the biomedical industry. Mr. McGlynn is also a founder and director of Life Science Angels. Since 2005 LSA has invested over $30 million in 40 life science companies that have received an additional $600 million of follow-on funding from venture investors.

 

Ned Scheetz, General Partner and Founder, Aphelion Capital

Ned Scheetz is the General Partner and founder of Aphelion Capital.  For over two decades, Mr. Scheetz has been an investor in numerous public and private healthcare companies.  Mr. Scheetz was a Partner and Managing Director with Piper Jaffray Ventures and a Senior Analyst with Janus Capital.  Prior to beginning his investment career, Mr. Scheetz held a number of sales and marketing positions with divisions of Eastman Kodak and Kraft General Foods.  Mr. Scheetz has served on a wide variety of corporate and non-profit boards in his career.
 
Mr. Scheetz is an advisory board member with the Center for Medical Device Innovation, and on the business advisory board of The Epilepsy Therapy Development Project.  A graduate of Duke University’s Fuqua School of Business, Colby College, and a post-graduate scholar at Oxford University, Mr. Scheetz also holds the CFA designation.

Paul Yock, MD, Director, Biodesign, Stanford University

Paul Yock is the Martha Meier Weiland Professor of Medicine and Mechanical Engineering (by courtesy) and Founding Co-Chair of Stanford’s Department of Bioengineering. He also holds a courtesy appointment on Operations, Information and Technology in the Stanford School of Business.

Dr. Yock is internationally known for his work in inventing, developing and testing new devices, including the Rapid Exchange™ balloon angioplasty system, which is now the primary system in use worldwide. He also invented a Doppler-guided access system known as the Smart Needle™ and PD-Access™.  The main focus of Dr. Yock’s research program has been in the field of intravascular ultrasound. He authored the fundamental patents for mechanical intravascular ultrasound imaging and helped conduct the initial clinical trials. In 1986 he founded Cardiovascular Imaging Systems, which was acquired by Boston Scientific in 1994. Dr. Yock has cofounded several other medical technology companies.

In his academic career Dr. Yock has authored over 300 peer-reviewed publications, chapters and editorials, a textbook and over 45 US patents. Recent awards include the Transcatheter Therapeutics (TCT) Career Achievement Award, the American College of Cardiology Distinguished Scientist Award and an honorary doctorate from Amherst College. Dr. Yock is a member of the National Academy of Engineering. Current research interests of Dr. Yock’s group at Stanford focus on development and testing of catheter-based delivery systems for cardiac cell transplantation and new catheter and molecular imaging techniques for cardiology. Dr. Yock also founded and directs the Program in Biodesign, a unit of Stanford’s Bio-X initiative that focuses on invention and technology transfer related to biomedical engineering.